A new study finds that a botanical drug could provide the key to new treatments for peanut allergies. The findings are published online in The Journal of Allergy and Clinical Immunology.
Lead author Xiu-Min Li, MD, Associate Professor of Pediatrics and Director of Center for Chinese Herbal Therapy for Allergy and Asthma at Mount Sinai School of Medicine and colleagues found Food Allergy Herbal Formula (FAHF-2) produced long-term protection following treatment against peanut-induced anaphylaxis in mice. FAHF-2 treatment protected peanut allergic mice from anaphylaxis for more than 36 weeks after treatment was discontinued. This is one-quarter of the mouse lifespan.
These findings update previous research done by Dr. Li and her colleagues, where the same drug was shown to be effective for preventing anaphylactic reactions for up to four weeks following treatment.
“Food allergy is a serious and sometimes fatal condition for which there is no cure,” said Dr. Li. “Approximately 80% of fatal or near-fatal anaphylaxis cases are due to peanut allergy in this country. There is an urgent need for effective therapies to prevent and treat those who suffer from food allergies and FAHF-2 could prove to be a major advancement in this field.”
FAHF-2 has received investigational new drug approval of the Food and Drug Administration and currently human clinical trials are being conducted at Mount Sinai to evaluate the safety and early efficacy of FAHF-2 on multiple food allergies including peanut, tree nut, fish and shellfish. “This study reinforces previous studies showing that this botanical drug has the potential to be developed into the first available and effective treatment for patients with peanut allergies and other food allergies,” said study co-author Hugh Sampson, MD, Professor of Pediatrics at Mount Sinai School of Medicine. Dr. Sampson is also Director of the Jaffe Food Allergy Institute and Dean for Translational Biomedical Science at The Mount Sinai Medical Center.
Cite This Page: